December 20, 2022 7:45am
Bottoms have yet to be defined, after another weak aftermarket narrows the drift of appreciation unless the algos “rule”
Indications: 2 Positive Indications and 1 Negative Indication
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
The Christmas holiday is starting for me with a limited review for the week, the 8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.13% or (+42 points), S&P futures are DOWN -0.03% or (-1 point) and NASDAQ futures are DOWN -0.33% or (-36 points) early in the pre-open – so far,
Stock futures struggled on Tuesday,
European markets were lower,
Asia-Pacific markets fell.
We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes dumped on Monday after posting their second straight week of losses for the first time since September
The Dow closed DOWN -162.92 points (-0.49%), the S&P closed DOWN -34.70 points (-0.90%) while the Nasdaq closed DOWN -159.38 points (-1.49%)
Economic Data Docket: housing starts data for November.
Monday’s (9/19) … RegMed Investors’ (RMi) closing bell: “residual negativity haunts our universe of cell and gene therapy is severely damaged. Declining sector equities (30) outnumbered advancers (4) with gene editors taking the downdraft the hardest as recession fears mount.” … https://www.regmedinvestors.com/articles/12750
Ebb and flow:
Q4 – December – 9 negative and 4 positive closes
· November -1 holiday, 14 negative and 8 positive closes
· October -1 neutral, 11 positive and 9 negative closes
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
BioLife Solutions (BLFS) closed up +$0.07 to $17.65 after Friday’s -$1.19 to $17.58, Thursday’s -$0.63 and Wednesday’s -$0.52 with a positive pre-open indication of +$0.15 or +0.85%.
Verve therapeutics (VERV) closed down -$1.30 to $17.97 after Friday’s -$0.25, Thursday’s -$3.09, Wednesday’s +$0.16 and last Tuesday’s -$0.32 with a positive pre-open indication of +$0.90 or +5.01%.
Voyager Therapeutics (VYGR) closed down -$0.12 to $5.81 with a negative -$0.05 or -0.86% aftermarket indication
The BOTTOM LINE: I try to keep it simple and short!
The new week’s start added to the percentage losses on the cell and gene therapy sector.
· Monday closed negative with 4 incliner, 30 decliners and 1 flat
· Friday closed negative with 16 incliner, 19 decliners and 0 flats
· Thursday closed negative with 6 incliner, 28 decliners and 1 flat
· Wednesday closed negative with 12 incliner, 23 decliners and 0 flat
· Tuesday closed positive with 26 incliner, 8 decliners and 1 flat
· Last Monday closed positive with 30 incliner, 3 decliners and 2 flats
Be prepared … just 8 trading days remain in 2022.
Until December 31, investors may want to be cautious about making new buys.
I’d be calculating selling for tax purposes amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.
Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.